Compare Aurobindo Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VENUS REMEDIES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VENUS REMEDIES AUROBINDO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 11.1 -1.0 - View Chart
P/BV x 2.0 0.1 2,867.3% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AUROBINDO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
VENUS REMEDIES
Mar-18
AUROBINDO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs830126 659.3%   
Low Rs52761 862.7%   
Sales per share (Unadj.) Rs333.9301.8 110.6%  
Earnings per share (Unadj.) Rs40.4-24.9 -162.3%  
Cash flow per share (Unadj.) Rs51.82.5 2,034.0%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.1293.3 80.8%  
Shares outstanding (eoy) m585.9112.34 4,748.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.00.3 655.9%   
Avg P/E ratio x16.8-3.8 -447.2%  
P/CF ratio (eoy) x13.136.7 35.7%  
Price / Book Value ratio x2.90.3 897.8%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5691,154 34,457.7%   
No. of employees `00017.90.9 1,930.3%   
Total wages/salary Rs m25,849393 6,575.6%   
Avg. sales/employee Rs Th10,956.94,026.1 272.1%   
Avg. wages/employee Rs Th1,447.7425.0 340.7%   
Avg. net profit/employee Rs Th1,324.3-331.8 -399.1%   
INCOME DATA
Net Sales Rs m195,6363,724 5,253.2%  
Other income Rs m1,55323 6,903.1%   
Total revenues Rs m197,1893,747 5,263.1%   
Gross profit Rs m39,519395 10,010.0%  
Depreciation Rs m6,680338 1,974.4%   
Interest Rs m2,626354 741.2%   
Profit before tax Rs m31,767-275 -11,539.1%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,26932 23,001.6%   
Profit after tax Rs m23,645-307 -7,704.5%  
Gross profit margin %20.210.6 190.5%  
Effective tax rate %22.9-11.5 -199.3%   
Net profit margin %12.1-8.2 -146.7%  
BALANCE SHEET DATA
Current assets Rs m153,6452,638 5,825.0%   
Current liabilities Rs m120,4292,305 5,225.5%   
Net working cap to sales %17.08.9 189.9%  
Current ratio x1.31.1 111.5%  
Inventory Days Days135135 99.8%  
Debtors Days Days6446 137.5%  
Net fixed assets Rs m103,9094,871 2,133.3%   
Share capital Rs m586123 474.8%   
"Free" reserves Rs m138,3223,496 3,956.9%   
Net worth Rs m138,9083,619 3,838.2%   
Long term debt Rs m1,8001,374 130.9%   
Total assets Rs m264,5447,509 3,523.3%  
Interest coverage x13.10.2 5,873.8%   
Debt to equity ratio x00.4 3.4%  
Sales to assets ratio x0.70.5 149.1%   
Return on assets %9.90.6 1,573.1%  
Return on equity %17.0-8.5 -200.7%  
Return on capital %23.81.6 1,506.7%  
Exports to sales %49.60-   
Imports to sales %18.813.9 135.4%   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741517 7,113.0%   
Fx inflow Rs m97,3160-   
Fx outflow Rs m40,589517 7,858.5%   
Net fx Rs m56,727-517 -10,983.0%   
CASH FLOW
From Operations Rs m16,220514 3,153.2%  
From Investments Rs m-28,768-123 23,369.9%  
From Financial Activity Rs m19,191-387 -4,957.5%  
Net Cashflow Rs m6,6564 158,485.7%  

Share Holding

Indian Promoters % 54.1 32.9 164.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 4,416.7%  
FIIs % 27.7 0.6 4,775.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 66.4 15.4%  
Shareholders   69,601 20,121 345.9%  
Pledged promoter(s) holding % 8.6 36.4 23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  DR. DATSONS LABS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)

This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Jan 6, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

I Made a Killing in the Markets this Week... Here's How(Profit Hunter)

Jan 10, 2020

How we made a killing in the markets amidst geopolitical tension and war mongering.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 17, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS